Comparative Efficacy of Stem Cells on Chronic Decompensated Cirrhosis: A Network Meta-analysis
1. Translational Medical Research Center, the Sixth People’s Hospital of Zhengzhou, Zhengzhou 450015,
2. Department of Radiology, Hebei Medical University, Shijiazhuang 050030,
3. Department of Liver Disease, the Sixth People’s Hospital of Zhengzhou, Zhengzhou 450015,
4. Department of Life Sciences, Faculty of Science and Engineering, Manchester Metropolitan University, Manchester M15GD, UK
5. Department of General Surgery, the Sixth People’s Hospital of Zhengzhou, Zhengzhou 450015,
| Abstract: | Currently, liver transplantation is the best way to improve the survival rate of decompensated cirrhosis, but its application is limited due to the shortage of donors and high cost. In the recent two decades, stem cell therapy is becoming a promising frontier alternative treatment. However, because various stem cell types, sources, and routes of administration can affect the therapeutic effect, we conducted this network meta-analysis to compare the efficacy of stem cells of different types, sources and delivery routes in the treatment of chronic decompensated cirrhosis. We retrieved the literature from PubMed, Embase, Cochrane Library, Web of Science from their establishment to December 2022. Additionally, clinicaltrials.gov was looked through for trials that had not yet been published or supplemental information that had been released as of December 2022. Only randomised controlled studies were included and patients must be aged at least 18 years and older with chronic decompensated liver cirrhosis but not acute-on-chronic liver failure. The included studies could be treated with stem cells of any source, type and route of administration. The primary outcome of measurement is the model of end-stage liver disease (MELD) score. This study has been registered with INPLASY (Registration number INPLASY202310050). From 2,374 articles, we included 18 studies with 936 patients. Our analysis showed no publication bias and revealed that human umbilical cord mesenchymal stem cells administered by artery and vein (hUCMSCsAV) can significantly improve MELD score of patients with chronic decompensated cirrhosis (SUCRA: 81.7%). Other effective stem cell approaches included ABMSCsA (SCURA： 65.7%), ABMSCsSH (SUCRA: 64.5%), ABMSCsGV (SUCRA: 63.5%), APBSCsGA (SUCRA: 58.7%), ABMNCsV (SUCRA: 54.9%), ABMSCsV (47.9%), and hUCMSCsV (46%). hUCMSCsAV was identified as the superior choice, followed by ABMSCsA. While these findings are promising, further high-quality research is necessary to confirm these results. |
| Keywords: | Stem Cells; Comparative Efficacy; Decompensated Liver Cirrhosis; Network Meta-Analysis |
| DOI: | 10.57237/j.cmf.2024.02.001 |
View:
Downloads:
Received: 19 June 2024
Accepted: 26 July 2024
Published Online: 29 July 2024
References
| [1] | Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019; 70(1): 151-171. |
| [2] | Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet. 2021; 398(10308): 1359-1376. |
| [3] | Shi L, Wang ZR, Li TT, Linghu EQ, Wang FS. Clinical research in cell therapy of liver diseases: progress and challenges. Chin J Hepatol. 2022; 30(3): 237-243. |
| [4] | Kuo TK, Hung SP, Chuang CH, et al. Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology. 2008; 134(7): 2111-2121, 2121.e2111-2113. |
| [5] | Schulz MS, Gu W, Schnitzbauer AA, Trebicka J. Liver Transplantation as a Cornerstone Treatment for Acute-On-Chronic Liver Failure. Transpl Int. 2022; 35: 10108. |
| [6] | Petersen BE, Bowen WC, Patrene KD, et al. Bone marrow as a potential source of hepatic oval cells. Science. 1999; 284(5417): 1168-1170. |
| [7] | Zakrzewski W, Dobrzyński M, Szymonowicz M, Rybak Z. Stem cells: past, present, and future. Stem Cell Res Ther. 2019; 10(1): 68. |
| [8] | Sudulaguntla A, Gurung S, Nanjwade BK, Tamang JKJJoP, Sciences P. A review: Stem cells and classification of stem cells based on their origin. 2016; 15(1): 105-112. |
| [9] | Siapati EK, Roubelakis MG, Vassilopoulos G. Liver Regeneration by Hematopoietic Stem Cells: Have We Reached the End of the Road? Cells. 2022; 11(15). |
| [10] | Liu Y, Dong Y, Wu X, Xu X, Niu J. The assessment of mesenchymal stem cells therapy in acute on chronic liver failure and chronic liver disease: a systematic review and meta-analysis of randomized controlled clinical trials. Stem Cell Res Ther. 2022; 13(1): 204. |
| [11] | Alwahsh SM, Rashidi H, Hay DC. Liver cell therapy: is this the end of the beginning? Cell Mol Life Sci. 2018; 75(8): 1307-1324. |
| [12] | Deng L, Kong X, Liu G, et al. Transplantation of Adipose-Derived Mesenchymal Stem Cells Efficiently Rescues Thioacetamide-Induced Acute Liver Failure in Mice. Transplant Proc. 2016; 48(6): 2208-2215. |
| [13] | Guo C, Han YJZgZBzzZGZCJoH. Current status, challenges and reflections on stem cell therapy for liver diseases. 2022; 30(3): 233-236. |
| [14] | Yu JW, Wang GQ, Li SCJJog, hepatology. Prediction of the prognosis in patients with acute-on-chronic hepatitis using the MELD scoring system. 2006; 21(10): 1519-1524. |
| [15] | Lau T, Ahmad J. Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine. Hepat Med. 2013; 5: 1-10. |
| [16] | Sun X, Guo S. Effectiveness of cell- and colony stimulating factor-based therapy for liver cirrhosis: a network meta-analysis of randomized controlled trials. Cytotherapy. 2022; 24(5): 516-525. |
| [17] | Arroyo V, Jalan R. Acute-on-Chronic Liver Failure: Definition, Diagnosis, and Clinical Characteristics. Semin Liver Dis. 2016; 36(2): 109-116. |
| [18] | Shah S, Goldberg DS. Acute-on-chronic liver failure: update on pathogenesis, therapeutic targets, predictive models, and liver transplantation. Curr Opin Gastroenterol. 2021; 37(3): 173-178. |
| [19] | EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018; 69(2): 406-460. |
| [20] | Asrani SK, Kim WR. Model for end-stage liver disease: end of the first decade. Clin Liver Dis. 2011; 15(4): 685-698. |
| [21] | Esmaeilzadeh A, Ommati H, Kooshyar MM, et al. Autologous bone marrow stem cell transplantation in liver cirrhosis after correcting nutritional anomalies, a controlled clinical study. Cell Journal. 2019; 21(3): 268-273. |
| [22] | Fang X, Liu L, Dong J, et al. A study about immunomodulatory effect and efficacy and prognosis of human umbilical cord mesenchymal stem cells in patients with chronic hepatitis B-induced decompensated liver cirrhosis. J Gastroenterol Hepatol. 2018; 33(4): 774-780. |
| [23] | Wu YZ, Yang L, Zhai YF, Zhang HH, Huo LY. Therapeutic effect of autologous bone marrow mesenchymal stem cells on hepatic fibrosis, liver function, MELD score and 1-year survival rate in patients with decompensated hepatitis B. Chinese journal of tissue engineering research. 2017; 21(13): 2049-2055. |
| [24] | Fang XQ, Zhang JF, Song HY, et al. Effects of human umbilical cord mesenchymal stem cell therapy on the immune function and prognosis in patients with decompensated liver cirrhosis due to hepatitis B. Chinese Journal of Tissue Engineering Research. 2017; 21(17): 2696-2701. |
| [25] | Suk KT, Yoon JH, Kim MY, et al. Transplantation with autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: Phase 2 trial. Hepatology. 2016; 64(6): 2185-2197. |
| [26] | Mohamadnejad M, Vosough M, Moossavi S, et al. Intraportal Infusion of Bone Marrow Mononuclear or CD133+ Cells in Patients With Decompensated Cirrhosis: A Double-Blind Randomized Controlled Trial. Stem Cells Transl Med. 2016; 5(1): 87-94. |
| [27] | Zeng ZY, Li DL, Fang J, et al. Umbilical cord mesenchymal stem cells with bone marrow stem cells in the treatment of decompensated cirrhosis: a 1-year follow-up study. Chinese journal of tissue engineering research. 2015; 19(10): 1533-1538. |
| [28] | Zekri ARN, Salama H, Medhat E, et al. The impact of repeated autologous infusion of haematopoietic stem cells in patients with liver insufficiency. Stem Cell Research and Therapy. 2015; 6(1). |
| [29] | Deng Q, Cai T, Zhang S, et al. Autologous peripheral blood stem cell transplantation improves portal hemodynamics in patients with hepatitis B virus-related decompensated cirrhosis. Hepatitis monthly. 2015; 15(12) (no pagination). |
| [30] | Xu L, Gong Y, Wang B, et al. Randomized trial of autologous bone marrow mesenchymal stem cells transplantation for hepatitis B virus cirrhosis: regulation of Treg/Th17 cells. Journal of gastroenterology and hepatology. 2014; 29(8): 1620-1628. |
| [31] | Wang QC, ZHang LY, Wang DL. Short-term effects of human umbilical cord-derived mesenchymal stem cells in treatment of patients with chronic liver failure. Chin J Gastroenterol Hepatol. 2013; 22(1): 22-24. |
| [32] | Mohamadnejad M, Alimoghaddam K, Bagheri M, et al. Randomized placebo-controlled trial of mesenchymal stem cell transplantation in decompensated cirrhosis. Liver Int. 2013; 33(10): 1490-1496. |
| [33] | Zhang Z, Lin H, Shi M, et al. Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. J Gastroenterol Hepatol. 2012; 27 Suppl 2: 112-120. |
| [34] | Lin H, Zhang Z, Shi M, et al. Evaluation on the efficacy of human umbilical cord derived-mesenchymal stem cell transplantation in liver cirrhosis patients with ascites in a prospective and control trial. Chin J Infect Dis. 2012; 30(4): 204-206. |
| [35] | El-Ansary M, Abdel-Aziz I, Mogawer S, et al. Phase II trial: undifferentiated versus differentiated autologous mesenchymal stem cells transplantation in Egyptian patients with HCV induced liver cirrhosis. Stem Cell Rev Rep. 2012; 8(3): 972-981. |
| [36] | Amer ME, El-Sayed SZ, El-Kheir WA, et al. Clinical and laboratory evaluation of patients with end-stage liver cell failure injected with bone marrow-derived hepatocyte-like cells. Eur J Gastroenterol Hepatol. 2011; 23(10): 936-941. |
| [37] | Peng L, Xie DY, Lin BL, et al. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology. 2011; 54(3): 820-828. |
| [38] | Nikeghbalian S, Pournasr B, Aghdami N, et al. Autologous transplantation of bone marrow-derived mononuclear and CD133+ cells in patients with decompensated cirrhosis. 2011. |
| [39] | Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PloS one. 2013; 8(10): e76654. |
| [40] | Salama H, Zekri AR, Medhat E, et al. Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease. Stem Cell Res Ther. 2014; 5(3): 70. |
| [41] | Dunn W, Jamil LH, Brown LS, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology. 2005; 41(2): 353-358. |
| [42] | Freeman RB, Jr., Wiesner RH, Harper A, et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl. 2002; 8(9): 851-858. |
| [43] | Lau T, Ahmad JJHme, research. Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine. 2013; 5: 1. |
| [44] | Can A, Celikkan FT, Cinar O. Umbilical cord mesenchymal stromal cell transplantations: A systemic analysis of clinical trials. Cytotherapy. 2017; 19(12): 1351-1382. |
| [45] | Yang H, Xie Y, Li T, Liu S, Zeng S, Wang B. A novel minimally invasive OFM technique with orthotopic transplantation of hUC-MSCs and in vivo monitoring of liver metabolic microenvironment in liver fibrosis treatment. Stem Cell Res Ther. 2021; 12(1): 534. |
| [46] | Zhang Y, Li Y, Zhang L, Li J, Zhu C. Mesenchymal stem cells: potential application for the treatment of hepatic cirrhosis. Stem Cell Res Ther. 2018; 9(1): 59. |
| [47] | Zhang LT, Peng XB, Fang XQ, Li JF, Chen H, Mao XR. Human umbilical cord mesenchymal stem cells inhibit proliferation of hepatic stellate cells in vitro. Int J Mol Med. 2018; 41(5): 2545-2552. |
| [48] | Baksh D, Yao R, Tuan RS. Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells. 2007; 25(6): 1384-1392. |
| [49] | Habeeb MA, Vishwakarma SK, Bardia A, Khan AA. Hepatic stem cells: A viable approach for the treatment of liver cirrhosis. World J Stem Cells. 2015; 7(5): 859-865. |
| [50] | Mäkelä T, Takalo R, Arvola O, et al. Safety and biodistribution study of bone marrow-derived mesenchymal stromal cells and mononuclear cells and the impact of the administration route in an intact porcine model. Cytotherapy. 2015; 17(4): 392-402. |
| [51] | Leibacher J, Henschler R. Biodistribution, migration and homing of systemically applied mesenchymal stem/stromal cells. Stem Cell Res Ther. 2016; 7: 7. |
| [52] | Kurtz AJIjosc. Mesenchymal stem cell delivery routes and fate. 2008; 1(1): 1-7. |
| [53] | Mahmood A, Seetharaman R, Kshatriya P, Patel D, Srivastava AS. Stem Cell Transplant for Advanced Stage Liver Disorders: Current Scenario and Future Prospects. Curr Med Chem. 2020; 27(37): 6276-6293. |
| [54] | Sarkar A, Saha S, Paul A, Maji A, Roy P, Maity TK. Understanding stem cells and its pivotal role in regenerative medicine. Life Sci. 2021; 273: 119270. |
| [55] | Tichy ED, Sidibe DK, Tierney MT, et al. Single Stem Cell Imaging and Analysis Reveals Telomere Length Differences in Diseased Human and Mouse Skeletal Muscles. Stem Cell Reports. 2017; 9(4): 1328-1341. |
| [56] | Peng L, Li H, Gu L, Peng XM, Huang YS, Gao ZL. Comparison of biological characteristics of marrow mesenchymal stem cells in hepatitis B patients and normal adults. World J Gastroenterol. 2007; 13(11): 1743-1746. |
| [57] | Lu LL, Liu YJ, Yang SG, et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica. 2006; 91(8): 1017-1026. |
| [58] | Hsieh JY, Fu YS, Chang SJ, Tsuang YH, Wang HW. Functional module analysis reveals differential osteogenic and stemness potentials in human mesenchymal stem cells from bone marrow and Wharton's jelly of umbilical cord. Stem Cells Dev. 2010; 19(12): 1895-1910. |
| [59] | Cho PS, Messina DJ, Hirsh EL, et al. Immunogenicity of umbilical cord tissue derived cells. Blood. 2008; 111(1): 430-438. |
| [60] | Deuse T, Stubbendorff M, Tang-Quan K, et al. Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells. Cell Transplant. 2011; 20(5): 655-667. |
| [61] | Yang X, Meng Y, Han Z, Ye F, Wei L, Zong C. Mesenchymal stem cell therapy for liver disease: full of chances and challenges. Cell Biosci. 2020; 10: 123. |
| [62] | Piscaglia AC, Campanale M, Gasbarrini A, Gasbarrini GJSCI. Stem cell-based therapies for liver diseases: state of the art and new perspectives. 2010; 2010. |
| [63] | Piscaglia AC, Novi M, Campanale M, Gasbarrini AJMIT, Technologies A. Stem cell-based therapy in gastroenterology and hepatology. 2008; 17(2): 100-118. |
| [64] | Rolando N, Clapperton M, Wade J, Wendon JJEjog, hepatology. Administering granulocyte colony-stimulating factor to acute liver failure patients corrects neutrophil defects. 2000; 12(12): 1323-1328. |
| [65] | Liu QJBp. Role of cytokines in the pathophysiology of acute-on-chronic liver failure. 2009; 28(4): 331-341. |
| [66] | Liongue C, Wright C, Russell AP, Ward ACJTijob, biology c. Granulocyte colony-stimulating factor receptor: stimulating granulopoiesis and much more. 2009; 41(12): 2372-2375. |
Join the Editorial Board
We invite active, qualified and high profile scientists and researchers to join as Editorial Board Members.
Join UsBecome a Reviewer
Scholars with a strong interest in reviewing are invited to join the reviewer panel to ensure the quality of the research to be published.
Join Us